Evidence map›Paper›PMID 27546618›Full record

ArticleOncogene2017

Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.

K Tominaga, T Shimamura, N Kimura, T Murayama, D Matsubara, H Kanauchi, A Niida, S Shimizu, K Nishioka, E-I Tsuji and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. The role of IGF/IGF-1R signaling in the regulation of cancer stem cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

K TominagaDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
T ShimamuraLaboratory of DNA information Analysis, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
N KimuraDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
T MurayamaDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
D MatsubaraDivision of Molecular Pathology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
H KanauchiDepartment of Breast and Endocrine Surgery, Showa General Hospital, Kodaira, Tokyo, Japan.
A NiidaLaboratory of DNA information Analysis, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
S ShimizuDepartment of Pathological Diagnosis, Showa General Hospital, Kodaira, Tokyo, Japan.
K NishiokaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
E-I TsujiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
M YanoDepartment of Surgery, Minami machida Hospital, Machida, Tokyo, Japan.
S SuganoLaboratory of Functional Genomics, Department of Medical Genome Sciences, Graduate School of Frontier Science, University of Tokyo, Minato-ku, Tokyo, Japan.
Y ShimonoDivision of Molecular and Cellular Biology, Kobe University, Graduate School of Medicine, Kobe, Japan.
H IshiiDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
H SayaDivision of Gene Regulation, Institute of Advanced Medical Research, Graduate School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
M MoriDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
K AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
K-I TadaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
T OgawaDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
A TojoDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
S MiyanoLaboratory of DNA information Analysis, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
N GotohDivision of Molecular Therapy, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
The University of Tokyo · JPTokyo University of Science · JPOsaka University · JPShowa General Hospital · JPKanazawa University · JPKeio University · JPKobe University · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transcription factor nuclear factor-κB (NF-κB) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-κB activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1R

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBiomarkers, TumorBreast NeoplasmsCarcinogenesisFemaleHumansInhibitor of Differentiation Protein 1Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMiceMice, NudeNeoplasm GradingNeoplasm InvasivenessNeoplasm MetastasisNeoplasm Recurrence, LocalBiomarkers, TumorID1 protein, humanIGF2 protein, humanInhibitor of Differentiation Protein 1Insulin-Like Growth Factor IInsulin-Like Growth Factor IINF-kappa BPhosphatidylinositol 3-Kinase

Identifiers

PMID27546618
PMCPMC5340799
OpenAlexW2508062996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.